CD19 and lupus nephritis: In pediatric lupus nephritis Anti-CD19 CAR-T cells, therapy achieved sustained remission a gradual decrease in inflammatory cytokines IL-6 and TNFα, along with the significant drop in SLE-associated antibodies in five out of six patients [15].